Search clinical trials for: Eylea

Total 279 results

Michel Giunta
Bayer

Active, not recruiting

Treat and Extend Analysis Trial With Aflibercept in Wet-AMD

Wet Age-related Macular Degeneration

Canada
Qilu Pharmaceutical Co., Ltd.

Completed

A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)

Wet Age-related Macular Degeneration

China
Singapore National Eye Centre
Santen Pharmaceutical Co., Ltd.; Singapore Eye Research Institute

Unknown

Diabetic Macular Edema Asian Response (DEAR) Study: Biomarkers for Response to Aflibercept in Asian Patients With Center Involving DME

Diabetic Macular Edema

Singapore
Vitreous -Retina- Macula Consultants of New York

Unknown

Intense Treatment Regimen With Intravitreal Aflibercept Injection (I-TRAP)

Neovascular Age-Related Macular Degeneration

United States
Moorfields Eye Hospital NHS Foundation Trust

Completed

VITAL - Individualising Therapy for Neovascular AMD With Aflibercept (VITAL)

Age Related Macular Degeneration

United Kingdom
Moorfields Eye Hospital NHS Foundation Trust
Bayer

Unknown

Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study (AMOUR)

Retinitis Pigmentosa | Macular Oedema

United Kingdom
Tennessee Retina
Regeneron Pharmaceuticals

Unknown

Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy

Retinal Vein Occlusion

United States
Unity Health Toronto

Recruiting

Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept (COVARIANT)

Diabetic Macular Edema | Macular Edema | Retinal Vein Occlusion | Age Related Macular Degeneration

Canada
Sam Chun Dang Pharm. Co. Ltd.

Completed

A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)

Neovascular Age-related Macular Degeneration | Wet Age-related Macular Degeneration

United States, Australia, Bulgaria, Czechia, Hungary, India, Israel, Japan, Korea, Republic of, Latvia, Poland, Russian Federation, Slovakia, Spain
Bayer

Completed

Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice

Wet Age-related Macular Degeneration

India
University of Alexandria

Completed

One Year Results of Switching to Aflibercept for Persistent Diabetic Macular Edema Resistant to Bevacizumab

Diabetic Macular Edema
Wake Forest University Health Sciences

Terminated

Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment

Retinal Vein Occlusion

United States
Ophthotech Corporation

Completed

A Study to Establish the Safety and Tolerability of Zimura® (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

Idiopathic Polypoidal Choroidal Vasculopathy

United States
Bayer

Completed

Special Drug Use Investigation of EYLEA for Diabetic Macular Edema

Macular Edema

Japan
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KINGFISHER)

Diabetic Macular Edema

United States, Hungary, Israel, Slovakia, Puerto Rico
Anders Kvanta

Completed

Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen

Central Retinal Vein Occlusion

Sweden
Bayer
Regeneron Pharmaceuticals

Completed

The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting (INSIGHT)

Wet Macular Degeneration

Sweden
Vista Klinik
Bayer

Completed

Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab

Neovascular Age-related Macular Degeneration
Retina Research Institute, LLC

Completed

Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome

Choroidal Neovascularization | Presumed Ocular Histoplasmosis

United States
Novartis Pharmaceuticals

Withdrawn

24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME. (TIDE DME)

Visual Impairment Due to Diabetic Macular Edema
Amgen
Parexel

Completed

A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]

Neovascular (Wet) Age-related Macular Degeneration (AMD)

Spain, United States, Czechia, Serbia, Israel, Canada, Germany, Japan, Hungary, Poland, Korea, Republic of, Estonia, Hong Kong, Italy, Latvia, Lithuania, Mexico, Slovakia
Bayer
Regeneron Pharmaceuticals

Terminated

A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment (XPAND)

Neovascular (Wet) Age-related Macular Degeneration

Canada, United Kingdom
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KESTREL)

Diabetic Macular Edema

United States, Austria, Japan, Australia, Spain, Canada, Israel, Netherlands, Italy, United Kingdom, Portugal, Colombia, Puerto Rico, Argentina
Sunnybrook Health Sciences Centre

Unknown

PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept (PRaCTICAL)

Age Related Macular Degeneration | Central Serous Chorioretinopathy | Idiopathic Poplypoidal Choroidal Vasculopathy

Canada
Associated Retinal Consultants, Michigan
Genentech, Inc.

Completed

Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept

Age-Related Macular Degeneration

United States
Vitreous -Retina- Macula Consultants of New York
Regeneron Pharmaceuticals

No longer available

Use of Eylea for the Treatment of an Optic Nerve Hemangioma

Retinal Hemangioma

United States
Unity Health Toronto

Unknown

Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study

Diabetic Macular Edema
Bayer

Recruiting

An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)

Preterm Infants | Retinopathy of Prematurity

United Kingdom
Bayer

Recruiting

A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity)

Retinopathy of Prematurity | Newborns | Infants

Japan
Amgen

Completed

A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)

Chorioretinal Vascular Disease

United States
Bayer

Completed

Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease (XTEND)

Wet Age-related Macular Degeneration

Canada, Spain, Sweden, Belgium, Argentina, Italy, Korea, Republic of, United Kingdom, China, Denmark, France, Norway, Colombia, Australia, Ireland, Switzerland, Thailand
Novartis Pharmaceuticals

Completed

To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema (KINGLET)

Diabetic Macular Edema

China
Bayer
Regeneron Pharmaceuticals

Completed

A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease (AURIGA)

Macular Edema

Germany, Italy, Russian Federation, Taiwan, China, Egypt, France, Kuwait, Lebanon, Saudi Arabia, United Arab Emirates
University of California, San Diego
Regeneron Pharmaceuticals

Completed

EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection (EAGLE)

Macular Degeneration | Wet Macular Degeneration

United States
Novartis Pharmaceuticals

Withdrawn

Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (BUZZARD)

Diabetic Macula Edema
Bayer

Completed

Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO (CENTERA)

Central Retinal Vein Occlusion

France, Canada, Denmark, Germany, Italy, Spain, United Kingdom, Australia
Bayer
Regeneron Pharmaceuticals

Completed

Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion (RETRO CRVO)

Retinal Vein Occlusion

Belgium
Wills Eye
Regeneron Pharmaceuticals

Completed

The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy (CONTAIN)

Central Serous Chorioretinopathy

United States
Asan Medical Center

Unknown

The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Diabetic Retinopathy

Diabetic Retinopathy

Korea, Republic of
Novartis Pharmaceuticals

Withdrawn

Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (TIDE DME)

Visual Impairment Due to Diabetic Macular Edema

Germany
Ophthotech Corporation

Withdrawn

ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

Idiopathic Polypoidal Choroidal Vasculopathy

United States
Bayer
Regeneron Pharmaceuticals

Completed

Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients (ASTERIA)

Wet Age-related Macular Degeneration

Switzerland
Pusan National University Hospital
Novartis

Unknown

Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study) (VIBIM)

Macular Edema, Diabetic

Korea, Republic of
Bayer

Recruiting

Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)

Neovascular Glaucoma

Japan
Novartis Pharmaceuticals

Completed

A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KITE)

Diabetic Macular Edema

Czechia, India, Russian Federation, Taiwan, Turkey, Lebanon, Denmark, Estonia, France, Germany, Hungary, Korea, Republic of, Latvia, Lithuania, Bulgaria, Norway, Belgium, Malaysia, Sweden, Slovakia, Singapore, Poland, Switzerland
King's College Hospital NHS Trust
King's College London

Completed

A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy. (VITCLEAR)

Age Related Macular Degeneration

United Kingdom
Gregg T. Kokame, MD
Regeneron Pharmaceuticals

Completed

Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation (EPIC)

Polypoidal Choroidal Vasculopathy

United States
Instituto de Olhos de Goiania

Completed

Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis

Glaucoma | Rubeosis Iridis

Brazil
Palmetto Retina Center, LLC

Unknown

Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910 (RANGE)

Exudative Age-related Macular Degeneration

United States
RemeGen Co., Ltd.

Recruiting

Efficacy and Safety of RC28-E Versus Aflibercept

Wet Age-related Macular Degeneration

China

3

Subscribe